Loading...

Immuron

DB:ANW
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ANW
DB
A$29M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Immuron has significant price volatility in the past 3 months.
ANW Share Price and Events
7 Day Returns
-0.4%
DB:ANW
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-34.1%
DB:ANW
-7.4%
DE Biotechs
-5.6%
DE Market
ANW Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immuron (ANW) -0.4% -6% -11.7% -34.1% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • ANW underperformed the Biotechs industry which returned -7.4% over the past year.
  • ANW underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
ANW
Industry
5yr Volatility vs Market

ANW Value

 Is Immuron undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Immuron. This is due to cash flow or dividend data being unavailable. The share price is €0.1325.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immuron's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immuron's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ANW PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.02
ASX:IMC Share Price ** ASX (2019-04-24) in AUD A$0.2
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immuron.

DB:ANW PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:IMC Share Price ÷ EPS (both in AUD)

= 0.2 ÷ -0.02

-10.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immuron is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Immuron is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Immuron's expected growth come at a high price?
Raw Data
DB:ANW PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immuron, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immuron's assets?
Raw Data
DB:ANW PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.05
ASX:IMC Share Price * ASX (2019-04-24) in AUD A$0.2
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:ANW PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:IMC Share Price ÷ Book Value per Share (both in AUD)

= 0.2 ÷ 0.05

3.99x

* Primary Listing of Immuron.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immuron is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Immuron's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immuron has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ANW Future Performance

 How is Immuron expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immuron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immuron expected to grow at an attractive rate?
  • Unable to compare Immuron's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Immuron's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Immuron's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:ANW Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ANW Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ANW Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:ANW Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -1 -3
2018-09-30 2 -2 -3
2018-06-30 2 -4 -3
2018-03-31 2 -6 -4
2017-12-31 2 -8 -5
2017-09-30 2 -8 -6
2017-06-30 1 -7 -7
2017-03-31 1 -5 -8
2016-12-31 1 -4 -6
2016-09-30 1 -5 -6
2016-06-30 1 -5 -7
2016-03-31 1 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Immuron is high growth as no earnings estimate data is available.
  • Unable to determine if Immuron is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ANW Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Immuron Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ANW Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:ANW Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.05
2017-06-30 -0.06
2017-03-31 -0.06
2016-12-31 -0.07
2016-09-30 -0.05
2016-06-30 -0.09
2016-03-31 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immuron will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Immuron's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Immuron's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Immuron's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Immuron's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immuron has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ANW Past Performance

  How has Immuron performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immuron's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immuron does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Immuron's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immuron's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immuron's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immuron Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ANW Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.90 -2.70 3.67 1.23
2018-09-30 1.87 -2.86 3.76 1.74
2018-06-30 1.84 -3.01 3.84 2.26
2018-03-31 1.73 -4.15 4.19 3.16
2017-12-31 1.61 -5.29 4.54 4.05
2017-09-30 1.50 -6.05 4.61 4.34
2017-06-30 1.40 -6.80 4.68 4.63
2017-03-31 1.30 -7.84 5.06 4.27
2016-12-31 1.21 -5.94 5.44 3.90
2016-09-30 1.10 -5.77 5.39 3.76
2016-06-30 1.00 -7.07 5.33 3.62
2016-03-31 0.99 -5.03 4.33 3.84
2015-12-31 0.97 -4.46 3.33 4.05
2015-09-30 0.99 -3.57 2.62 3.53
2015-06-30 1.00 -2.69 1.91 3.02
2015-03-31 1.03 -2.50 1.69 2.40
2014-12-31 1.19 -2.42 1.35 1.77
2014-09-30 1.12 -2.48 1.40 1.53
2014-06-30 0.98 -2.50 1.51 1.29
2014-03-31 0.71 -3.02 1.69 1.07
2013-12-31 0.37 -3.49 1.93 0.86
2013-09-30 0.26 -3.52 1.73 0.93
2013-06-30 0.15 -3.54 1.54 1.00
2013-03-31 0.03 -3.00 1.62 1.04
2012-12-31 -0.08 -2.47 1.70 1.08
2012-09-30 0.18 -2.38 1.94 1.15
2012-06-30 0.45 -2.30 2.19 1.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immuron has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immuron has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immuron improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immuron's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immuron has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ANW Health

 How is Immuron's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immuron's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immuron is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immuron has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immuron's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Immuron has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immuron Company Filings, last reported 3 months ago.

DB:ANW Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7.18 0.00 4.19
2018-09-30 7.18 0.00 4.19
2018-06-30 8.44 0.00 4.73
2018-03-31 8.44 0.00 4.73
2017-12-31 4.98 0.05 0.59
2017-09-30 4.98 0.05 0.59
2017-06-30 6.57 0.37 3.99
2017-03-31 6.57 0.37 3.99
2016-12-31 3.55 0.68 3.10
2016-09-30 3.55 0.68 3.10
2016-06-30 4.94 1.90 2.29
2016-03-31 4.94 1.90 2.29
2015-12-31 1.94 1.02 0.99
2015-09-30 1.94 1.02 0.99
2015-06-30 4.81 0.00 3.12
2015-03-31 4.81 0.00 3.12
2014-12-31 5.50 0.00 4.57
2014-09-30 5.50 0.00 4.57
2014-06-30 6.79 0.00 6.14
2014-03-31 6.79 0.00 6.14
2013-12-31 -1.05 0.00 0.35
2013-09-30 -1.05 0.00 0.35
2013-06-30 0.14 1.15 1.45
2013-03-31 0.14 1.15 1.45
2012-12-31 0.60 0.63 0.44
2012-09-30 0.60 0.63 0.44
2012-06-30 2.05 0.56 1.44
  • Immuron has no debt.
  • Immuron had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immuron has sufficient cash runway for more than 3 years based on current free cash flow.
  • Immuron has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -14.4% each year.
X
Financial health checks
We assess Immuron's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immuron has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ANW Dividends

 What is Immuron's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immuron dividends.
If you bought €2,000 of Immuron shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immuron's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immuron's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ANW Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ANW Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immuron has not reported any payouts.
  • Unable to verify if Immuron's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immuron's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immuron has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Immuron's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immuron afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immuron has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ANW Management

 What is the CEO of Immuron's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gary Jacob
AGE 71
TENURE AS CEO 0.4 years
CEO Bio

Dr. Gary S. Jacob, Ph.D., has been Chief Executive Officer of Immuron Limited since November 19, 2018 and has been its Director since April 17, 2019. He serves as Chairman of the Board of ContraVir Pharmaceuticals, Inc. since March 19, 2014 and its Director since May 15, 2013. Dr. Jacob served as the Chief Executive Officer and President of ContraVir Pharmaceuticals, Inc. from May 15, 2013 to March 19, 2014. He served as Chief Executive Officer and President at Synergy Pharmaceuticals, Inc. since July 2008 to December 31, 2017. Dr. Jacob served as the Chief Executive Officer of Callisto Pharmaceuticals Inc. from May 2003 to January 2013. He served as Secretary of TrovaGene, Inc. since February 2009. Dr. Jacob served as an Acting Chief Executive Officer and President of Pawfect Foods Inc. since July 2008. He served as an Acting Chief Executive Officer of Callisto Pharmaceuticals, Inc. He served as the Chief Scientific Officer of Synergy Pharmaceuticals Inc. from 1999 to 2003. From 1990 to 1998, he served as a Monsanto Science Fellow, specializing in the field of Glycobiology. From 1997 to 1998, Dr. Jacob served as Director of Functional Genomics, Corporate Science & Technology at Monsanto Company. He has been an Independent Director of TrovaGene, Inc. since February 2009. He served as the Chairman of Synergy Pharmaceuticals, Inc. from September 2003 to November 2011. He served as Executive Chairman at Synergy Pharmaceuticals Inc. from September 2013 to October 31, 2018 and served as its Director from July 2008 to October 31, 2018. He served as an Executive Director of Callisto Pharmaceuticals, Inc. from October 2004 to January 2013. From 1990 to 1997, he served as a Director of Glycobiology, G.D. Searle Pharmaceuticals Inc. From 1986 to 1990, he served as Manager of the G.D. Searle Glycobiology Group located at Oxford University, England. He served as a Director of Pawfect Foods, Inc. since July 2008. Dr. Jacob has over thirty years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Dr. Jacob holds Ph.D. in Biochemistry from the University of Wisconsin-Madison. He holds BS in Chemistry from University of Missouri-Columbia.

CEO Compensation
  • Insufficient data for Gary to compare compensation growth.
  • Insufficient data for Gary to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Peter Anastasiou

TITLE
Executive Vice Chairman
COMPENSATION
A$50K
AGE
58

Jerry Kanellos

TITLE
Chief Operating Officer
COMPENSATION
A$227K
AGE
57
TENURE
3.8 yrs

Gary Jacob

TITLE
CEO & Director
AGE
71
TENURE
0.4 yrs

Phillip Hains

TITLE
CFO & Company Secretary
AGE
59

David Lyon

TITLE
Head of Marketing
Board of Directors Tenure

Average tenure and age of the Immuron board of directors in years:

6.2
Average Tenure
61
Average Age
  • The tenure for the Immuron board of directors is about average.
Board of Directors

Roger Aston

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$90K
AGE
62
TENURE
7.1 yrs

Peter Anastasiou

TITLE
Executive Vice Chairman
COMPENSATION
A$50K
AGE
58
TENURE
3.9 yrs

Gary Jacob

TITLE
CEO & Director
AGE
71

Daniel Pollock

TITLE
Independent Non-Executive Director
COMPENSATION
A$66K
AGE
58
TENURE
6.5 yrs

Stephen Anastasiou

TITLE
Independent Non-Executive Director
COMPENSATION
A$50K
AGE
61
TENURE
5.9 yrs

Arun Sanyal

TITLE
Member of Advisory Board

Stephen Harrison

TITLE
Member of Advisory Board

Manal Abdelmalek

TITLE
Member of Advisory Board

Gerhard Rogler

TITLE
Member of Advisory Board

Miriam Vos

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Immuron's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immuron has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ANW News

Simply Wall St News

ANW Company Info

Description

Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers’ diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.

Details
Name: Immuron Limited
ANW
Exchange: DB
Founded: 1994
A$17,973,626
143,215,706
Website: http://www.immuron.com.au
Address: Immuron Limited
62 Lygon Street,
Level 3,
Carlton,
Victoria, 3053,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX IMC Ordinary Shares Australian Securities Exchange AU AUD 30. Apr 1999
DB ANW Ordinary Shares Deutsche Boerse AG DE EUR 30. Apr 1999
CHIA IMC Ordinary Shares Chi-X Australia AU AUD 30. Apr 1999
NasdaqCM IMRN SPONSORED ADR Nasdaq Capital Market US USD 18. Jan 2008
Number of employees
Current staff
Staff numbers
0
Immuron employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:17
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2018/08/30
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.